| 1 |
27599706 | Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes. | 2017 Apr |
1 |
| 2 |
26296069 | Physiologically based pharmacokinetics model predicts the lack of inhibition by repaglinide on the metabolism of pioglitazone. | 2015 Dec |
1 |
| 3 |
22942318 | Statistical methods for analysis of time-dependent inhibition of cytochrome p450 enzymes. | 2012 Dec |
1 |
| 4 |
18783297 | General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information. | 2008 |
1 |
| 5 |
17201456 | Pharmacokinetic interactions with thiazolidinediones. | 2007 |
1 |
| 6 |
16447051 | Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. | 2006 Mar |
3 |
| 7 |
16867170 | Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. | 2006 Jul |
4 |
| 8 |
17214065 | The pharmacokinetics of pioglitazone in Thai healthy subjects. | 2006 Dec |
1 |
| 9 |
15900286 | Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. | 2005 May |
2 |
| 10 |
16283275 | Effect of gemfibrozil on the pharmacokinetics of pioglitazone. | 2005 Dec |
1 |
| 11 |
16372821 | Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. | 2005 |
1 |
| 12 |
12642470 | Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. | 2003 Apr |
2 |
| 13 |
11921435 | Differentiating members of the thiazolidinedione class: a focus on safety. | 2002 Mar-Apr |
2 |
| 14 |
12463723 | Pioglitazone: effect on CYP3A4 activity. | 2002 Dec |
3 |